Skip to content
Triangle logo TriangleGet started
← Full study record

NCT00313729 · OUTCOME

Safety Profile

Temozolomide in Treating Patients With Low-Grade Glioma · Source last updated 2019-02-07

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
COUNT_OF_PARTICIPANTS
Unit
Participants
Interval / dispersion
Not reported
Time frame
Time from registration up to 13 months

What was measured

Number of participants with treatment related grade 2-4 adverse events as defined by CTCAE 3.0

Groups in this outcome

Temozolomide

Temozolomide temozolomide: Chemotherapy

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
Temozolomide120

Reported measurements

Source class 1
Values in Participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Temozolomide12Not reportedNot reportedNot reportedNot reported
Complete source fields
classes
  1. categories
    1. measurements
      1. group Id
        OG000
        value
        12
denoms
  1. counts
    1. group Id
      OG000
      value
      120
    units
    Participants
description
Number of participants with treatment related grade 2-4 adverse events as defined by CTCAE 3.0
groups
  1. description
    Temozolomide temozolomide: Chemotherapy
    id
    OG000
    title
    Temozolomide
param Type
COUNT_OF_PARTICIPANTS
reporting Status
POSTED
time Frame
Time from registration up to 13 months
title
Safety Profile
type
SECONDARY
unit Of Measure
Participants

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice